GlassScriptPhysician profile
Fei Lian
NPI 1699169169
$11,045.49
in general payments reported to CMS, 2019-2025
45 companies · $5,361 in 2025
The $5,361 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $462 · 2021: $504 · 2022: $1,157 · 2023: $1,182 · 2024: $2,380 · 2025: $5,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,100 · Consulting Fee: $2,650 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,110 · Travel and Lodging: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.65 |
| Consulting Fee | $2,650.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,110.00 |
| Travel and Lodging | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,904.72 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $1,547.31 | 2025 | Erleada |
| Procept Biorobotics Corporation | $580.29 | 2022 | |
| Coloplast Corp | $529.19 | 2020-2023 | Titan |
| Endo USA, INC. | $504.59 | 2024-2025 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $481.41 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $478.51 | 2022-2025 | Provenge |
| Urogen Pharma, INC. | $301.66 | 2023-2025 | Jelmyto |
| Janssen Biotech, INC. | $289.07 | 2022-2025 | Erleada |
| Urovant Sciences INC | $282.87 | 2021-2022 | |
| Blue Earth Diagnostics | $261.30 | 2023-2025 | Posluma |
| Teleflex LLC | $237.64 | 2021-2025 | Urolift |
| Astellas Pharma US INC | $218.73 | 2022-2025 | Myrbetriq, Xtandi |
| Ferring Pharmaceuticals INC. | $199.59 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $197.77 | 2023-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $157.07 | 2021-2024 | Xiaflex, Aveed |
| Johnson & Johnson Health Care Systems INC. | $148.50 | 2025 | |
| Abbvie INC. | $124.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $118.94 | 2021-2025 | Keytruda, Lynparza |
| Immunitybio, INC. | $115.17 | 2025 | |
| Accord Healthcare, INC. | $111.04 | 2023-2025 | |
| Tempus Ai, INC | $107.92 | 2024 | Xt Cdx |
| Myovant Sciences INC. | $106.72 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $104.42 | 2023-2025 | Lynparza |
| Telix Pharmaceuticals | $103.82 | 2023-2025 | Illuccix |
| Progenics Pharmaceuticals, INC. | $95.56 | 2023-2025 | Pylarify |
| Baxter Healthcare | $94.53 | 2024 | Tisseel |
| Sun Pharmaceutical Industries INC. | $71.12 | 2024-2025 | |
| Olympus America INC. | $70.18 | 2021-2025 | Itind System, Tecoflex |
| Antares Pharma, INC. | $63.72 | 2024-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $57.86 | 2024 | |
| Axonics, INC. | $49.68 | 2022-2023 | Axonics |
| Amgen INC. | $48.63 | 2023 | Prolia |
| Alnylam Pharmaceuticals INC. | $33.13 | 2023-2025 | Givlaari |
| Vertex Pharmaceuticals Incorporated | $31.50 | 2025 | |
| 180 Medical, INC. | $27.68 | 2021 | |
| Halozyme INC | $26.63 | 2023 | |
| Steris Corporation | $25.21 | 2024 | |
| Tolmar, INC. | $24.49 | 2025 | Eligard, Jatenzo |
| Novo Nordisk INC | $22.59 | 2024 | Rivfloza |
| Tolmar Pharmaceuticals, INC. | $21.91 | 2021 | |
| Calyxo, INC. | $19.33 | 2025 | Cvac Aspiration System |
| Millicent US INC | $19.13 | 2023 | Femring, Intrarosa |
| Verity Pharmaceuticals INC. | $16.88 | 2025 | Trelstar |
| Laborie Medical Technologies Corp. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fei Lian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.